Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galectin-9 is a member of the galectin family of beta-galactoside-binding lectins. It contains two carbohydrate recognition domains (CRDs) and is widely expressed in various tissues. It functions as an immunomodulator, inducing apoptosis of activated T cells and regulating Th17/Treg balance. It interacts with receptors such as HAVCR2/TIM3, CLEC7A, CD137, and CD40 on immune cells. Galectin-9 also plays roles in tumor biology, suppressing tumor metastasis and influencing angiogenesis. Intracellularly, it acts as a lysosome stress sensor, linking lysosomal damage to mTOR inhibition via AMPK signaling. It is implicated in allergic responses and has emerged as a promising target for cancer immunotherapy.
Modulation of immune cell function; induction of apoptosis; regulation of T cell balance; lysosomal stress response via AMPK/mTOR pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Galectin-9.